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In an earlier edition of Muscle & Nerve, we outlined how psychological processes interact 
with biological and social factors to affect quality of life in muscle disorders (1). We then 
described the use of psychological interventions – focusing mainly on talking therapies – for 
improving quality of life, mood and general functioning. As in the case of well-cited reviews 
describing the clinical management of myotonic dystrophy (2, 3), neuropsychological 
assessment and cognitive rehabilitation were not described in detail in our article. The work 
by Fujino et al. (4), published in this issue of Muscle & Nerve, suggests that, in the care of 
patients with myotonic dystrophy (Type 1) at least, the lack of attention to cognitive 
rehabilitation may have been an oversight. Therefore, in this commentary we discuss the 
clinical implications of Fujino et al., (4), taking the opportunity to describe the potential for 
cognitive rehabilitation for myotonic dystrophy.  
 
Fujino and colleagues (4), observed that a large proportion of their participants had quite 
severe myotonic dystrophy and demonstrated impairment in at least one cognitive domain 
(i.e. scores at least two standard deviations from population averages). Impairment 
occurred most frequently in the domains of executive functioning, processing speed, 
attention, and visuoconstruction. Although this study included no controls for the impact of 
marked motor impairment, this finding adds to a body of work showing that many people 
with myotonic dystrophy type 1 experience cognitive difficulties (5, 6). Consistent with 
existing work (7), a significant proportion of participants in the sample recruited by Fujino et 
al. [4] demonstrated co-morbid behavioural symptoms/changes - with higher levels of 
apathy and depression apparent in the sample. 
 
The aetiology of cognitive and behavioural symptoms in Fujino et al.’s [4] sample was 
unclear. Other studies have found an association between unstable cytosine–thymine–
guanine (CTG) repeat expansion size and cognitive test performance and behaviour changes 
in myotonic dystrophy (5, 6, 8). This is unsurprising given that, in myotonic dystrophy type 1, 
a positive association exists between brain pathology and CTG repeat expansion (9), while 
the extent of white matter lesions is positively correlated with cognitive impairment and 
behavioural symptoms (10, 11). In addition, other contextual factors – which may be less 
dependent on underlying brain pathology - might also affect cognitive functioning. Reactive 
depression, perhaps resulting from difficulties adjusting to physical symptoms, may worsen 
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performance on cognitive testing; fatigue, sleepiness, or pain may also lead to problems 
with effort.  
 
Importantly, Fujino et al. (4) demonstrated that performance on several cognitive tests was 
positively correlated with psychosocial aspects of quality of life. The cross-sectional design 
does not allow us to disentangle the direction of influence between these variables. Yet, this 
observation does raise the possibility that an improvement in cognitive symptoms, or their 
impact on functioning, could lead to an improvement in quality of life. Although a caveat is 
that some reduced insight may be protective of mood (12), cognitive rehabilitation might 
offer a means to improve outcomes for many people with myotonic dystrophy.  
 
The role of Neuropsychology in the care of myotonic dystrophy  
Cognitive rehabilitation involves two stages: an assessment of cognitive functioning, 
followed by consequent treatment recommendations. Below, we discuss each stage, with 
some salient discussion points emerging from Fujino et al. (4).  
 
1. Characterising a cognitive and behavioural profile 
Cognitive rehabilitation initially entails carrying out a clinical interview and a formal 
assessment of cognitive functioning – to generate a cognitive and behavioural profile. The 
clinical interview comprises discussion with the patient and someone who knows them well 
(e.g. spouse, family member, friend). To estimate expected cognitive functioning, questions 
are asked about the patient’s educational background and developmental history. 
Questioning may then switch to examining cognitive failures, behaviour changes, mood and 
everyday adjustment. This information can be contrasted against estimates of expected 
functioning to suggest those cognitive domains that are likely to be affected and therefore 
should be formally assessed.   
 
A formal assessment may then be undertaken, using standardised cognitive tests: cognitive 
screens, comprehensive test batteries or focal assessment batteries. A cognitive screen (e.g. 
Repeatable Battery for the Assessment of Neurological Status; RBANS (13)), involving brief 
tests covering many cognitive domains (e.g. memory, executive functioning, visuospatial 
functioning, and processing speed), may be administered to assess whether comprehensive 
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or focal neuropsychological testing is likely to be of informative.  Comprehensive test 
batteries, such as the Wechsler Adult Intelligence Scale (WAIS) (14), are alternatively or 
subsequently administered to patients. Such batteries involve detailed testing of many 
cognitive domains. If indicated, extended testing of a single cognitive domain may also be 
informative – helping pinpoint more exactly the locations of cognitive impairment. For 
example, batteries such as the Wechsler Memory Scale (WMS) (15) or the Delis Kaplan 
Executive Function Scale (DKEFS) (16) can be used to comprehensively assess memory and 
executive functioning respectively. Raw test scores are then compared to population norms 
to generate metrics indicating deviations from expected scores, resulting in a cognitive 
profile. Once a patient’s cognitive profile is characterised (domains where they have 
perform as expected or have strengths, weaknesses and impairments), then information 
from the clinical interview helps to inform what may explain any findings of impairment. 
 
In light of this information, intervention may take several forms (described in the next 
sections).  Yet there are possible therapeutic benefit of cognitive profile characterisation 
alone (17). First, in clinic we often note that, for many people, fears about cognitive 
impairment and excessive attention toward cognitive errors detrimentally affects mood and 
functioning. Therefore, for those individuals where cognitive impairment was 
suspected/feared but is not apparent after assessment, cognitive assessment can provide 
reassurance and reduce pre-occupation with possible cognitive symptoms.  
 
Second, such an assessment might enable a change in perspective for the person with 
myotonic dystrophy and the system around them – including their clinicians. There is a 
sizable literature describing aberrant personality profiles in myotonic dystrophy (see(3)). 
Such a focus on personality may risk the blurring of symptoms (neurocognitive, behavioural 
symptoms/behaviour or the impact of muscle pathology) with the person who is living with 
them. Given underlying neuro- and muscle pathology, disease-linked neurocognitive or 
behavioural changes (e.g. theory of the mind difficulties (18), apathy (4) or other 
neuropsychiatric features (12)) and/or the impact of living with muscle symptoms (pain, 
fatigue etc.) may be a more accurate conceptualisation than personality difficulties. If we 
accept this, then we might more readily see a separation between the person and their 
symptoms; viewing the person as finding themselves in a difficult context which involves 
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living with myotonic dystrophy-caused symptoms (as opposed to being an apathetic person 
etc.). This may: a) foster greater empathy for the person living with the condition among 
their clinicians, family and care-givers- as well as self-compassion, and b) in the case of 
neurocognitive and behavioural symptoms, emphasize that these are not just due to a 
person’s personality but rather are a change or symptom of disease, and may therefore be 
targets for treatment/clinical research.  
 
In the study by Fijuno et al. (4) a notable limitation was that, in addition to secondary 
factors such as pain that were outlined above, muscle pathology may have confounded test 
performance. Several of the cognitive tests employed in their study require timed or 
accurate physical responses, such as drawing (e.g. the Trail-Making Test or figure copy). It is 
possible that myotonia and muscle weakness could impede responses - leading to 
erroneous assumptions of cognitive impairment. Therefore, myotonia and muscle weakness 
should be considered when selecting neuropsychological tests. Tests that do not require 
hand movements may be of value. For example, a newer cognitive screen developed for ALS 
- the Edinburgh Cognitive and Behavioural ALS Screen (19) – has an alternate form requiring 
verbal response alone. However, speech may also be affected in myotonic dystrophy type 1, 
and difficulties with articulation could also affect test performance. In addition, test length 
should also be carefully considered because another confounding factor in assessing 
performance on cognitive testing can be fatigue or sleepiness (20). Similarly, the impact of 
muscle symptoms, speech, fatigue or difficulties adjusting to the condition may impact the 
measurement of behaviour changes. Thus, nuanced or multiple-dimension measures of, for 
example, apathy (Dimensional Apathy Scale (21)) may be more informative than the single-
domain measure used in Fujino et al. [4]. 
 
2. Cognitive rehabilitation  
Although one case study exists (22), we are unaware of any clinical trials of cognitive 
rehabilitation in myotonic dystrophy. There is a promising literature from trials of cognitive 
rehabilitation for multiple sclerosis (23) that  may be generalizable to myotonic dystrophy. 
Thus, if there are significant everyday cognitive difficulties, and especially if they are borne 
out by impairments on cognitive assessment, then interventions might be worth 
considering.  
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Interventions could take several forms depending on the individual’s insight and aspirations, 
the role of secondary factors including motor disability, medical prognosis, family support or 
stress, and the individual’s cognitive profile as determined by neuropsychological testing. 
Intervention first involves ascertaining the key goals for the individual and his family. Next, 
one should consider the role of secondary factors such as fatigue and pain, and the extent 
to which they can be modified. Psychoeducation will include increasing the patient’s (and 
possibly their family’s and caregiver’s) awareness of the individual’s cognitive weaknesses 
and strengths. Compensatory methods may then be suggested to reduce the impact of 
cognitive impairments. For example, patients may be supported to make beneficial 
alterations to their home or work environment such as reducing clutter/proximity to 
distraction and keeping consistency in object placement or to use external aids such as 
smart-phones, notebooks, and diaries. Families, including the person with myotonic 
dystrophy, and carers may also get together to discuss how they can change how they 
interact in light of cognitive difficulties.  Internal strategies such as mnemonics and visual 
imagery can be used to compensate for weakness in learning or retaining information(24). 
Of interest, there is also some, albeit lower-quality, evidence that more direct cognitive 
training could have some modest impact on working memory in multiple sclerosis (23), 
suggesting the possibility of a similar approach for people living with myotonic dystrophy 
type 1.  
 
The work by Fujino et al. [4] suggests that clinicians working with myotonic dystrophy type 1 
may be most often required to make suggestions for impairments in executive functioning, 
processing speed, and attention. Some compensatory recommendations might include goal 
management training approaches that have been successfully applied to improve executive 
functioning in people with neurological conditions (25) and the use of cueing systems to 
keep participants focused on tasks and adhere to rules (24). From our clinical experience, 
other potentially helpful rehabilitation techniques for disorders of executive functioning 
include problem solving training, encouraging patients to plan, break down tasks and 
monitor solutions. Also, metacognitive or self-instructional training may be useful as a 
means to counteract impulsivity.    
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Finally, if mood or psycho-social factors appear to be significant contributors to cognitive or 
everyday functioning, then psychological interventions such as talking therapies may also be 
helpful (see Graham et al., (1) for an outline of these treatments).  
 
Conclusion 
The study by Fujino et al. [4] emphasises that cognitive impairment and behavioural 
changes are often apparent in severe myotonic dystrophy type 1, and that such 
impairments are associated with quality of life. While there is a lack of empirical study of 
cognitive rehabilitation in myotonic dystrophy, given these findings, we suggest that clinical 
neuropsychology has a role in myotonic dystrophy care. Clinicians should be careful in 
choosing cognitive tests and measures of behaviour symptoms/behaviour change, as the 
muscle weakness and myotonia, fatigue, pain, depression and apathy may affect test scores. 
Yet, the characterisation of a cognitive and behavioural profiles may be beneficial and could 
lead to fruitful recommendations for intervention.  
 
List of abbreviations 
ALS = Amyotrophic Lateral Sclerosis 
CTG = cytosine–thymine–guanine 
D-KEFS = Delis Kaplan Executive Function Scale 
DM1 = myotonic dystrophy type 1 
RBANS = Repeatable Battery for the Assessment of Neurological Status 
WAIS = Wechsler Adult Intelligence Scale 
WMS = Wechsler Memory Scale 
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